{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:55Z","timestamp":1791825355608,"version":"4.3.4"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jtim-2025-0034_s_008\">\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>Few studies have provided real-world data on the biochemical response, risk assessment, and prognosis of patients with primary biliary cholangitis (PBC)-related decompensated cirrhosis undergoing ursodeoxycholic acid therapy. The objective of this study is to define recompensation in this patient population based on the BAVENO VII criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0034_s_009\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective analysis included 170 patients with cirrhosis who presented with ascites, hepatic encephalopathy, and\/or variceal bleeding as their initial decompensating events at Xijing Hospital from 2006 to 2023. Events of further decompensation, liver transplantation, and liver-related death were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0034_s_010\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Alkaline phosphatase (ALP) had complex prognostic value in patients with PBC-related decompensated cirrhosis receiving ursodeoxycholic acid therapy. In patients with normal total bilirubin (TBIL) at the 1-year follow-up, elevated ALP was associated with poor prognosis (hazard ratio [HR]: 2.57, 95% confidence interval [CI]: 1.12-5.87, <jats:italic>P<\/jats:italic> = 0.025), whereas in those with elevated TBIL, decreased ALP was associated with poor prognosis (HR: 0.53, 95% CI: 0.26-1.08, <jats:italic>P<\/jats:italic> = 0.082). A Model for End-Stage Liver Disease score &lt; 10 and the absence of decompensating events from the last decompensated state over the next 12 months were used to assess PBC recompensation. During follow-up, 26% (45\/170) of patients experienced at least one episode of recompensation. Compared with observations in the non-recompensation group, the recompensation group exhibited a longer liver transplantation-free survival (HR: 16.48, 95% CI: 2.23-121.57, <jats:italic>P<\/jats:italic> = 0.006), lower rates of further decompensation (22% <jats:italic>vs<\/jats:italic>. 63%, <jats:italic>P<\/jats:italic> &lt; 0.001), a significant reduction in high-risk patients (<jats:italic>P<\/jats:italic> &lt; 0.05, all), and notable improvements in serum indicators (platelet count, TBIL, albumin, and international normalized ratio). Baseline platelet and TBIL levels, the 1-year Rotterdam criteria, and severe interface hepatitis were associated with recompensation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jtim-2025-0034_s_011\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We defined PBC recompensation as a Model for End-Stage Liver Disease score &lt; 10 and the absence of decompensating events from the last decompensated state for the next 12 months, aligned with the requirements of BAVENO VII for patients with PBC-related decompensated cirrhosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jtim-2025-0034","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T14:55:44Z","timestamp":1753973744000},"page":"366-374","source":"Crossref","is-referenced-by-count":5,"title":["Definition and validation of recompensation in patients with primary biliary cholangitis-related decompensated cirrhosis treated with ursodeoxycholic acid: Based on the BAVENO VII criteria"],"prefix":"10.1515","volume":"13","author":[{"given":"Dawei","family":"Ding","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Cui","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Jia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boling","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Sun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Shang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5115-1632","authenticated-orcid":false,"given":"Guanya","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-9507","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, National Clinical Research Center for Digestive Diseases, Xijing Hospital, The Air Force Military Medical University , Xi'an , Shaanxi Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"2025082207593377915_j_jtim-2025-0034_ref_001","doi-asserted-by":"crossref","unstructured":"Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. Lancet Gastroenterol Hepatol 2020;5:306\u2013315.","DOI":"10.1016\/S2468-1253(19)30343-7"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_002","doi-asserted-by":"crossref","unstructured":"Lleo A, Wang GQ, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet 2020;396:1915-1926.","DOI":"10.1016\/S0140-6736(20)31607-X"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_003","doi-asserted-by":"crossref","unstructured":"Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 2020;17:93\u2013110.","DOI":"10.1038\/s41575-019-0226-7"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_004","doi-asserted-by":"crossref","unstructured":"Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1423\u20131434.","DOI":"10.1111\/jgh.15329"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_005","doi-asserted-by":"crossref","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044\u20131051.","DOI":"10.1053\/gast.2002.36027"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_006","doi-asserted-by":"crossref","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chr\u00e9tien Y, Andr\u00e9ani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48:871\u2013877.","DOI":"10.1002\/hep.22428"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_007","doi-asserted-by":"crossref","unstructured":"Mayo MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?Hepatology 2022;76:518\u2013531.","DOI":"10.1002\/hep.32405"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_008","doi-asserted-by":"crossref","unstructured":"Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol 2019;71:357\u2013365.","DOI":"10.1016\/j.jhep.2019.04.001"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_009","doi-asserted-by":"crossref","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394\u2013419.","DOI":"10.1002\/hep.30145"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_010","doi-asserted-by":"crossref","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022;75:1012\u20131013.","DOI":"10.1002\/hep.32117"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_011","doi-asserted-by":"crossref","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76:959\u2013974.","DOI":"10.1007\/978-3-031-08552-9"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_012","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_013","doi-asserted-by":"crossref","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology 2015;149:1804\u20131812.","DOI":"10.1053\/j.gastro.2015.07.061"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_014","doi-asserted-by":"crossref","unstructured":"D'Amico G, Zipprich A, Villanueva C, Sord\u00e0 JA, Morillas RM, Garcovich M, et al. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 2024;79:869\u2013881.","DOI":"10.1097\/HEP.0000000000000652"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_015","doi-asserted-by":"crossref","unstructured":"Ding D, Jia G, Cui L, Liu Y, Wang X, Sun R, et al. The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system. Dig Liver Dis 2025;57:861\u2013868.","DOI":"10.1016\/j.dld.2024.12.024"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_016","doi-asserted-by":"crossref","unstructured":"You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, et al. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022;16:1\u201323.","DOI":"10.1007\/s12072-021-10276-6"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_017","doi-asserted-by":"crossref","unstructured":"Gazda J, Drazilova S, Gazda M, Janicko M, Koky T, Macej M, et al. Treatment response to ursodeoxycholic acid in primary biliary cholangitis: A systematic review and meta-analysis. Dig Liver Dis 2023;55:1318\u20131327.","DOI":"10.1016\/j.dld.2022.12.010"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_018","doi-asserted-by":"crossref","unstructured":"Ding D, Xuan G, Hu Y, Yu J, Liu Y, Guo G, et al. Immunoglobulin M: A Neglected Serum Biomarker in Treatment-Naive Primary Biliary Cholangitis With Normal Alkaline Phosphatase. Hepatol Commun 2022;6:1403\u20131412.","DOI":"10.1002\/hep4.1907"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_019","doi-asserted-by":"crossref","unstructured":"Hui VW, Wong GL, Wong VW, Chan HL, Lai JC, Tse YK, et al. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis. JHEP Rep 2023;5:100814.","DOI":"10.1016\/j.jhepr.2023.100814"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_020","doi-asserted-by":"crossref","unstructured":"Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis. J Hepatol 2022;77:1564\u20131572.","DOI":"10.1016\/j.jhep.2022.07.037"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_021","doi-asserted-by":"crossref","unstructured":"Hofer BS, Simbrunner B, Hartl L, Jachs M, Balcar L, Paternostro R, et al. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis. Liver Int 2023;43:2220\u20132231.","DOI":"10.1111\/liv.15676"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_022","doi-asserted-by":"crossref","unstructured":"Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun 2022;6:3487\u20133495.","DOI":"10.1002\/hep4.2103"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_023","doi-asserted-by":"crossref","unstructured":"Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63:930\u2013950.","DOI":"10.1002\/hep.28017"},{"key":"2025082207593377915_j_jtim-2025-0034_ref_024","doi-asserted-by":"crossref","unstructured":"Ding D, Guo G, Cui L, Jia G, Wang X, Zhang M, et al. Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria. Hepatol Int 2024;18:206\u2013215.","DOI":"10.1007\/s12072-023-10587-w"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0034\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0034\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T08:01:51Z","timestamp":1755849711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2025-0034\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,8,22]]}},"alternative-id":["10.1515\/jtim-2025-0034"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2025-0034","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]}}}